INS and Hypoglycemia: The SHINE trial demonstrated that intensive glucose control targeting 80–130 mg/dL via continuous insulin infusion did not result in a significant improvement in 90-day functional outcomes compared to standard subcutaneous insulin therapy and was associated with a markedly higher incidence of severe hypoglycemia (2.6% vs. 0%) [117].